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The experiment adopting reverse transcription polymerase chain reaction (RT-PCR) technology, 
amplified hVEGF165 gene fragments from human leukemia cells HL-60. hVEGF165 gene was 
reconstructed in pIRES2-EGFP and transferred into the human placenta-derived mesenchymal stem 
cells (HPMSCs) by liposome-mediated method successfully. The mRNA and protein of hVEGF165 in the 
transferred cells was detected by RT-PCR and Western blot, and the results showed that 
hVEGF165mRNA and the protein expressed by HPMSCs transfected with pIRES2-EGFP-hVEGF165 was 
significantly more than HPMSCs transfected with pIRES2-EGFP. EGFP expression was observed under 
fluorescence microscope, which proved that the report gene was successfully transferred to the target 
cells. hVEGF biology activity and cell proliferation activity of HPMSCS transfected with pIRES2-EGFP-
hVEGF165 was detected by MTT array, which showed that hVEGF165 can promote the proliferation of 
HPMSCS; however, hVEGF165 biology activity of HPMSCS transfected with pIRES2-EGFP-hVEGF165 
was significantly more than HPMSCs transfected with pIRES2-EGFP. Identification of multipotentiality 
showed that HPMSCS transfected with pIRES2-EGFP-VEGF165 still maintained multipotentiality. 
 





Vascular endothelial growth factor is a potent factor for 
promoting angiogenesis, and this can induce 
angiogenesis (Parati et al., 2003), increase vascular 
permeability (Jackson et al., 2001), maintain vascular 
function and play an important role in wound healing. The 
focus of the current research is to use growth factor in the 
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Abbreviations: VEGF, Vascular endothelial growth factor; 
BMSCS, bone marrow mesenchymal stem cells; ADSCs, 
adipose-derived stem cells; HPMSCs, human placenta-derived 
mesenchymal stem cells; RT-PCR, reverse transcription 
polymerase chain reaction; DMSO, dimethylsulfoxide. 
combined radiation and wound injury, etc.), whose family 
has five subtypes with VEGF165 as the most important 
phenotype. Since the vascular endothelial growth factor 
(VEGF) half-life is short (that is, about 30 to 45 min in 
normal tissues, and can be extended to 6 to 8 h in the 
ischemic area), it requires a delivery system to extend the 
time of vascular endothelial growth factor in wound repair 
parts. 
It was discovered that the bone marrow mesenchymal 
stem cells (Halleux et al., 2001) and adipose-derived 
stem cells (Lei et al., 2007) had important application 
potential in the field of wound healing in recent years, in 
that they can locally extend homing to trauma (Kajstura et 
al., 2005) and directionally differentiate them into wound 
repair cells, endothelial cells and fibroblasts (Brittan et al., 
2005).  However,  they  can  prompt  the  regeneration  of  
 




endogenous cells in tissues through creating and 
enhancing repaired microenvironment (Fathke et al., 
2004; Badiavas et al., 2003), thereby accelerating wound 
healing. Stem cells are also good carrier cells for gene 
therapy and can carry target genes to target areas to play 
a treatment role (Badiavas et al., 2003). Human placenta-
derived mesenchymal stem cell is a significant source of 
adult stem cells, which gradually attracted attention in 
recent years. The author shows that (Liu et al., 2009) 
HPMSCs are basically consistent with bone marrow 
mesenchymal stem cells (BMSCs) in morphological and 
biological trait aspects and can directly differentiate them 
into wound repair cells and endothelial cells
 
in certain 
conditions through studies (Liu et al., 2010), which 
indicated that human placenta-derived mesenchymal 
stem cells (HPMSCs) can be used as seed cells for 
wound repair. 
The study successfully constructed pIRES2-EGFP-
VEGF165, and it was transfected into HPMSCs by 
liposome-mediated, so that vascular endothelial growth 
factor can be stably expressed for a long time. This not 
only plays the long effect mechanism of VEGF, but also 
exerts the function of HPMSCs to prompt trauma healing, 
thereby laying a prophase experiment foundation for 
studying the further application of vascular endothelial 
growth factor transgenic stem cell transplantation method 
in the treatment of refractory wound healing. 
 
 




Primer synthesis (cyagen biosciences), RT-PCR kit (Promega), 
agarose (Promega), T4 phage DNA ligase (Promega), restriction 
endonuclease EcoRI, BamHI (Takara), DNA gel extraction kit 
(Promega), DNA-Marker (Sigma USA), plasmid extraction kit 
(Promega), Trizol (Sigma USA), ethidium bromide (EB) (Sigma 
USA), IMDM medium (Sigma USA), fetal calf serum (Hyclone), 
pMD18 T vector (Clontech USA), pIRES2-EGFP (Clontech USA), 
human leukemia cells HL-60 (presented by Doctor Shen Weizhang 
of the Second Hospital of Jilin University), E. coli DH5α 
(Biochemical and Molecular Biology Lab of Bethune Medical 
School), HPMSCS (cultured and identified in our laboratory) (Liu et 
al., 2009) and the abandoned placenta (from the Department of 
Obstetrics and Gynecology, Second Hospital, Jilin University), were 
used for this study. HPMSCS belong to the adult stem cells, which 
do not involve ethical issues, such as lipofectin lipids body 
suspension (GIBCO), DEME medium (GIBCO), ECV304 (presented 
by the Department of Biochemistry, Basic Medical College) and 
G418 selection medium (Protec Company). Construction and 
identification of pIRES2-EGFP-hVEGF165 
 
 
Acquisition, amplification and identification of target gene 
fragments hVEGF165 
 
Trizol was used to extract HL-60 cell total RNA. The RNA 
concentration was determined, and it was best when A260/A280 
ratio was 1.8. The first chain of cDNA was synthesized through 
using Oligo (dT) and M-MLV reverse transcriptase according to the 
instructions. hVEGF165 full-length gene sequences were searched 





ATG on the upstream and terminating with the stop codon TGA on 
the downstream was designed. EcoRI and BamHI restriction 
endonuclease enzyme digestion site sequences were added on the 
upstream and downstream primers respectively, and they were sent 
to cyagen biosciences for synthesizing hVEGF165 primer 
sequences: upstream comprised 5'-CGGAATTCATGAACTTT 
CTGCTGTCTTGGGTG-3', containing EcoRI restriction endo-
nuclease enzyme digestion sites; while downstream comprised 5'-
CGGGATCCTCACCGCCTCGGCTTGTCACATCT-3', containing 
BamHI restriction endonuclease enzyme digestion sites. 
Polymerase chain reaction (PCR) products passed through 
agarose gel electrophoresis, and the rubber of the target strips was 
cut, reclaimed and purified. The purified hVEGF165 PCR products 
were connected to pMD18-T vector, while the ligation product was 
transformed into competent cells DH5α. Colony growth conditions 
were observed, and the positive bacteria colony was screened by 
blue and white spot screening. PCR screening was carried out after 
culture, and finally, the pMD18-T-hVEGF165 enzyme digestion 
identification was carried out.  
 
 
Construction and identification of pIRES2-EGFP-hVEGF165 
 
EcoRI and BamHI double digests were identified for pMD18-T-
hVEGF165 and pIRES2-EGFP, while T4DNA ligase was used for 
connecting stick ends of these products. pIRES2-EGFP-hVEGF165 
was built and transformed into competent cells DH5α. However, 
reverse transcription polymerase chain reaction and double digest 
identification of pIRES2-EGFP-hVEGF165 was carried out. 
 
 
pIRES2-EGFP-hVEGF165 transfected HPMSCs  
 
About 1 ml serum-free DEME was used for diluting pIRES2-EGFP-
hVEGF165 and pIRES2-EGFP, which was revolved for 1 s, and 
was added to Lipofectin liposome suspension, then scrolled again 
and placed at room temperature for 5 to 10 min so that the two 
parts could be combined, that is, pIRES2-EGFP-hVEGF165-
Lipofectin and pIRES2-EGFP-Lipofectin were prepared. There were 
three groups: Group A was HPMSCS with an addition of pIRES2-
EGFP-hVEGF165-Lipofectin, Group B was HPMSCS with an 
addition of pIRES2-EGFP-Lipofectin, and Group C was the control 
group (pIRES2-EGFP-Lipofectin without HPMSCS). The cells were 
screened by G418 selection.  
 
 
Identification of VEGF activity expressed by HPMSCs 
transfected with pIRES2-EGFP-hVEGF165 
 
1. Western blot analysis of hVEGF165 protein obtained from bone 
marrow mesenchymal stem cells transfected with pIRES2-EGFP-
hVEGF165.  
2. The VEGF biology activity expressed by HPMSCS transfected 
with pIRES2-EGFP-hVEGF165 and MTT array human endothelial 
cell line ECV304 was seeded on 96-well plates, and added to each 
group of transfection supernatant with 1/2 volume. MTT solution 
was added and continuously cultured for 4 h, and then 
dimethylsulfoxide (DMSO) solution (100 µl) was added and shaken 
until the blue settlement was fully dissolved and the D480 value was 
measured. Subsequently, the statistical data were adopted as mean 
± standard deviation (× ± S), and t test was adopted for group 
comparison.  
3. Proliferation activity identification of HPMSCS transfected with 
hVEGF165 amid MTT array. Pass cells with excellent growth were 
respectively selected and seeded on 96-well plates. Each well was 
added to the cell suspension (200 µl) of each group and the 20 µl 
MTT solution (5 mg/ml). After culturing for 36 h, it was added to 








Figure 1. PT-PCR products. Lane 1: Marker; 




was selected and the optical density was measured. Statistical data 
were adopted as mean ± standard deviation (× ± S), and t test was 
adopted for group comparison.  
4. Observation of transfection result under fluorescence microscopy 
and flow cytometry analysis of transfection efficiency.  
 
 





It has a DMEM-HG induction system containing 10% FBS, 
dexamethasone (1 µM), anti-inflammatory pain (200 µM), IBMX (0.5 





It has a 2.5% FBS DMEM-HG induction system added with insulin, 
transferrin, sodium selenite (6.25 µg/ml), BSA (1.25 µg/ml), sodium 
pyruvate (1 mM / L), ascorbic acid phosphate (37.5 µg/ml) and 





Construction and identification of pIRES2-EGFP-
hVEGF165  
 
Amplification of target gene fragment  
 
hVEGF165 gene sequence has the full length of 576bp 
and the total length of 592 bp after adding enzyme 
digestion sequences and protective genes on the 
upstream and downstream. Reverse transcription poly-
merase chain reaction (RT-PCR) products were obtained 
for electrophoresis on agarose gel, and target strips 
appeared on about 600 bp of the DNA marker (Figure 1), 
which indicated that the amplification of the target gene 
fragment succeeded.  






Figure 2. Electrophoresis of 
pMD18-T-hVEGF165 double 





Double digestion identification of pMD18-T-
hVEGF165  
 
The electrophoresis results of the restricted incision 
enzyme, EcoRI and BamHI double digestion recombinant 
cloning vector (Figure 3), showed that a strip appeared 
on nearly 600 bp of the DNA Marker with the same size 
of the target fragment, which indicated the successful 
connection between the segment and the vector. 
 
 
Enzyme digestion identification of pIRES2-EGFP-
hVEGF165  
 
The electrophoresis result showed that recombinant 
comprised the fragment that is consistent with the target 
fragments, which indicated that the fragment was 




pIRES2-EGFP-hVEGF165 transfected HPMSCs  
 
1. Groups A and B had a little survived cells at the 
seventh day through selection with about one to five cells 
in each low time field of vision. Group A generated a 
positive cell clone 15 days after screening by G418 
selective medium, which indicated that both effects of 
HPMSCs transfected with pIRES2-EGFP-hVEGF165 and 
G418 selection are better (Figure 4). 
2. RT-PCR verified expression of hVEGF165: It can be 
seen   on   gel   image  analysis  system  that  hVEGF165  
 






Figure 3. Electrophoresis result of 
EcoRI, BamHI double digestion 
pIRES2-EGFP-hVEGF165. Lane 1: 
pIRES2-EGFP; lane 2: pIRES2-






Figure 4. Fifteen days after HPMSCS were transfected 
with pIRES2-EGFP-VEGF165 through screening by 




expression of group A is prominently intensified when 
compared with group B. Fragment expression being 
consistent with the size of the target fragment can also be 
seen on group B, β-actin218 gene transcript was used as 







Figure 5. Detection of hVEGF165 mRNA in HPMSCS 





3. Western blot analysis of hVEGF165 protein expres-
sion: A strip with weak expression can be seen in group 
B, while a stronger strip can be seen in group A;  
however, β-actin218 gene transcript was used as a 
reference template (Figures 7 and 8). 
4. Check of vascular endothelial growth factor biology 
activity with MTT array: Results showed that the VEGF 
biological activity expressed by HPMSCS of group A was 
prominently more than that of groups B and C, and that of 
group B was more than that of group C. Nonetheless, all 
the results were statistically significant (Table 1 and 
Figure 9). 
5. Proliferation activity identification of human placenta-
derived mesenchymal stem cells by MTT array: The 
results showed that the proliferation activity of HPMSCs 
in group A was significantly increased when compared 
with group B (Table 2 and Figure 10).  
6. Observation of the transfection result under 
fluorescence microscopy and flow cytometry analysis of 
transfection efficiency: A large amount of human 
placenta-derived mesenchymal stem cells expressing 
green fluorescence can be seen in groups A and B after 
transfection for 48 h, and the 48 to 72 h was the 
expression peak period of green fluorescence. The 
expression decreased after  1  week,  and  the  enhanced  
 













Figure 7. Detection of VEGF165 protein in HPMSCS by western-








































Table 1. Influence of HPMSCS culture supernatant on hECV304 
proliferation activity. 
 





t tests of groups A and B were compared two by two (P < 0.01); t tests 
of group A and the control group were compared two by two (P < 
0.01); t tests of group B and the control group were compared two by 










Table 2. Proliferation activity identification of HPMSCS by MTT 
array. 
 










































Figure 11. HPMSCs transfected with PIRES2–EGFP–




green fluorescent protein expression was still visible until 
the third week (Figure 11). The transfection efficiency was 
46.8% after transfection for 72 h, detected by flow 
cytometry analysis.  
 
 
Identification of the multipotentiality of HPMSCs 
transfected with pIRES2-EGFP-hVEGF165  
 
It can be seen under adipose cell induction environment 
that fat generated in cells was specifically stained to be 
red (Figure 12), while in the cartilage induction 
environment, the stroma outside the cells formed by a 






Gene therapy, which is currently the world's most popular 
field of research, has virtually pervaded various fields of 
medical research. The essential role of Vascular 
endothelial growth factor (VEGF) in promoting wounds’ 
healing has commonly been permitted by scholars, but 
simply using VEGF has the disadvantages of short half-
life, poor penetration, easy absorption of extracellular 
matrix and low biological utilization rate. Such negative 
factors greatly restricted its clinical application. Along with 
the rapid development of molecular biology, the 
transgenic technology makes vascular endothelial growth 
factor in the wounds efficient and long-lasting expression, 
which can overcome the direct application of exogenous 
VEGF165 faults (Vescovi et al., 1993). Using stem cells 
as a purpose of gene carrier, can not only play its role of  






Figure 12. HPMSCS transfected with pIRES2-EGFP-hVEGF165 






Figure 13. Stroma outside HPMSCS transfected with 
pIRES2-EGFP-hVEGF165 formed by a type of Ⅱ 
collagen was specifically stained to be blue in vitro 




wound healing, but can also carry target genes to target 
areas. Moreover, it has the great potential for refractory 
wounds healing. Based on these considerations, 
amplified target gene fragments hVEGF165 were 
acquired from leukemia cell HL–60 by RT–PCR. pIRES2-
EGFP-hVEGF165 was constructed and the enzyme 
digestion identification of pIRES2-EGFP-hVEGF165 was 
used to evaluate the successful construction of the 
plasmid.  
 




Human placenta-derived mesenchymal stem cells 
(HPMSCS) was transfected with pIRES2-EGFP-hVEGF-
165 by liposome-mediated. The liposome-mediated gene 
transfection method is one of the most commonly used 
methods, and the technology is mature, safe and reliable. 
The method has the advantages that: (1) it is simple, and 
can carry larger DNA molecules (Zhou et al., 1994); (2) it 
is more secure and can transfect more types of cells, and 
target cells do not need to be in the division state. 
Wherein the application of carrier system (plasmids) 
mediated with cationic liposome is the widest, it is non-
immunogenic, non-toxic and non-carcinogenic, and can 
be easily prepared for large amount. The transfection 
efficiency is not as high as the viral vectors, but it has 
passed the United States National Institutes of Health 
(NIH) and the recombinant DNA Advisory Committee 
(RAC) for approval as a gene therapy vector to be 
introduced into the phase of II clinical trials, and is used 
for the treatment of certain cancers (Nabel et al., 1992). 
Therefore, the experiment adopted liposome-mediated 
pIRES2-EGFP-hVEGF165 to transfect HPMSCs from the 
comprehensive consideration on the aspects such as 
post animal experiment security and the likes of others. In 
so doing, VEGF can be expressed in transgenic HPMSCS 
efficiently and stably, which not only accords the 
requirements of gene therapy for wound healing, but also 
avoids the potential defects in the virus vector mediated 
gene therapy. Green fluorescence can be seen in groups 
A and B under fluorescence microscopy, which suggested 
that the reported genes were successfully transfected 
into target cells, and it was proved that it was feasible for 
human placenta-derived mesenchymal stem cells 
transfected with PIRES2–EGFP–hVEGF165 by 
liposome-mediated. RT-PCR and western blot analysis 
verified a stronger expression of vascular endothelial 
growth factor obtained from HPMSCs transfected with 
PIRES2–EGFP–hVEGF165 than from HPMSCs trans-
fected with PIRES2–EGFP, which indicated that vascular 
endothelial growth factor had been successfully 
transferred to human placenta-derived mesenchymal 
stem cells on one hand, and HPMSCs had an endocrine 
function of VEGF on the other hand. 
Influence of human placenta-derived mesenchymal 
stem cells culture supernatant on hECV304 proliferation 
activity was detected by MTT array, and the results 
suggested that vascular endothelial growth factor was 
expressed continuously and effectively after being 
transfected into human placenta-derived mesenchymal 
stem cells. The HPMSCs transfected with pIRES2-EGFP 
also had an expression of vascular endothelial growth 
factor, thereby suggesting that human placenta-derived 
mesenchymal stem cell had an endocrine function of 
vascular endothelial growth factor itself. Cell proliferation 
activity changes of human placenta-derived mesen-
chymal stem cells were detected by MTT array, and the 
results suggested that pIRES2-EGFP-hVEGF165 had 





prominent prompting role to the proliferation of human 
placenta-derived mesenchymal stem cells. 
We further carried out a multiple differentiation induction 
identification on HPMSCs transfected with PIRES2–
EGFP–hVEGF165 in order to prevent it from generating 
genetic mutation and losing multipotentiality. The results 
showed that the transgenic human placenta-derived 
mesenchymal stem cells still maintain the stem cell 
characteristics of multipotentiality. 
To sum up, the experiment successfully constructed the 
pIRES2-EGFP-hVEGF165 and utilized the liposome 
transfection method to successfully transfer it into human 
placenta-derived mesenchymal stem cells, where 
hVEGF165 had stronger expression in HPMSCs and was 
correctly decorated on one hand, which indicated that 
human placenta-derived mesenchymal stem cells can be 
used as carrier cells of hVEGF165 gene therapy. Human 
placenta-derived mesenchymal stem cells transfected 
with hVEGF165 gene can achieve a long-term release 
role of vascular endothelial growth factor, and it was also 
suggested that HPMSCs had endocrine hVEGF165 
function on the other hand, but the effect was weak, in 
that VEGF has a significant promoting role to value 
adding of human placenta-derived mesenchymal stem 
cells. Conclusively, this experiment sets the former 
experiment’s foundation for later application of HPMSCs 
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